Formycon AG announces amendment to the proposal for election of a Supervisory Board member (agenda item 9) in the context of the Annual General Meeting on June 30, 2022

DGAP-News: Formycon AG / Key word(s): AGM/EGM/Miscellaneous
Formycon AG announces amendment to the proposal for election of a Supervisory Board member (agenda item 9) in the context of the Annual General Meeting on June 30, 2022
28.06.2022 / 12:45
The issuer is solely responsible for the content of this announcement.

Press Release // June 28, 2022

Formycon AG announces amendment to the proposal for election of a Supervisory Board member (agenda item 9) in the context of the Annual General Meeting on June 30, 2022

Munich – Based on the resolution of the Supervisory Board of Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) dated June 27, 2022, the election proposal under agenda item 9 of the agenda for the 2022 Annual General Meeting of Formycon AG published in the Federal Gazette on May 20, 2022 shall be amended. The Supervisory Board of Formycon AG now proposes Dr. Thomas Strüngmann for election as a member of the Supervisory Board.

In a statement to the Supervisory Board dated June 27, 2022, the initially proposed candidate declared that she was no longer available for the proposed election to the Supervisory Board of the Company for personal reasons.

The Supervisory Board wants to adhere to the proposed elections to the Supervisory Board in the interests of the Company. Against the background of the new fact that the originally proposed candidate is no longer available, the Supervisory Board cannot adhere to its previous proposed resolution and has therefore amended it accordingly.

The Supervisory Board is convinced of the qualification of Dr. Thomas Strüngmann as a candidate for the Supervisory Board, in particular due to his outstanding competence profile, his many years of experience in the pharmaceutical industry, and his comprehensive industry and technical knowledge. Further information on the candidate can be found at:

https://www.formycon.com/en/investor-relations/annual-general-meeting/

Based on the resolution of the Supervisory Board, the proposed resolution on agenda item 9 of the invitation to the Annual General Meeting is amended as follows:

Elections to the Supervisory Board

The expansion of the Supervisory Board to four members proposed under agenda item 8 will, under German law, take effect upon entry into the Commercial Register of the respective amendment to the Articles of Incorporation.

The Supervisory Board of Formycon AG will thereupon, under the amended sec. 6 no. 1 of the Articles of Incorporation, consist of four members, each to be elected by a general meeting of shareholders. In its election of members of the Supervisory Board, the general meeting of shareholders is not bound by nominations.

To fill this additional future Supervisory Board position, it is proposed that this Annual General Meeting elect a fourth member of the Supervisory Board. It should be noted, however, that the term of office of the newly elected member will not begin until the expansion of the Supervisory Board enters into force.

Athos KG, which indirectly holds a total of 26.6% of the shares of Formycon AG by way of Santo Holding AG (Zug, Switzerland), Klinge Biopharma GmbH and FYB 202 GmbH & Co. KG, has in its capacity as a shareholder proposed Dr. Thomas Strüngmann for election to the Supervisory Board. Following its own examination, the Supervisory Board has considered and adopted this shareholder proposal and, against this background, herewith proposes Dr. Thomas Strüngmann for election as a member of the Supervisory Board in accordance with sec. 124 para. 3 sentence 1 of the Stock Corporation Act. Dr. Thomas Strüngmann has expressed his accordance with this proposal of the Supervisory Board and declared his intention to stand for election to the Supervisory Board.

The Supervisory Board therefore proposes, subject to and beginning with the entry into force of the amendment to the Articles of Incorporation proposed under the above agenda item 8, that

Dr. Thomas Strüngmann,
residing in Bad Wiessee,
Entrepreneur, especially in the pharmaceutical industry and principal of ATHOS KG,

be elected as a member of the Company’s Supervisory Board for a term of office ending with the Annual General Meeting which decides upon the ratification of the acts of Supervisory Board members for the fourth fiscal year following the start of this term of office, whereby the fiscal year during which the term of office begins is not included.

The Supervisory Board has obtained assurance from the candidate that he will be able to devote the expected amount of time to her work on the Supervisory Board.

Further information on the proposed candidate (curriculum vitae) is available to shareholders on the Company's website prior to and during the virtual Annual General Meeting at

https://www.formycon.com/en/investor-relations/annual-general-meeting/

About Formycon:
Formycon (ISIN: DE000A1EWVY8 / WKN: A1EWVY) is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development. Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 drug FYB207.

About Biosimilars:
Since their introduction in the 1980s, biopharmaceuticals have revolutionized the treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, multiple sclerosis and eye diseases. In the coming years, many of these biotech drugs will lose their patent protection – and by 2020, medications with revenues of approximately USD 100 billion will be off patent. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product. Global sales of biosimilars are estimated to exceed $15 billion by 2020. By 2030, analysts estimate that this figure could rise to over $60 billion.

Contact:
Sabrina Müller
Senior Manager Corporate Communications and Investor Relations
Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg/Germany
phone +49 (0) 89 - 86 46 67 149
fax + 49 (0) 89 - 86 46 67 110
Sabrina.Mueller@formycon.com // www.formycon.com

Disclaimer:
This press release may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.

28.06.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de